SG11202008513WA - De-immunised anti-erbb3 antibodies - Google Patents
De-immunised anti-erbb3 antibodiesInfo
- Publication number
- SG11202008513WA SG11202008513WA SG11202008513WA SG11202008513WA SG11202008513WA SG 11202008513W A SG11202008513W A SG 11202008513WA SG 11202008513W A SG11202008513W A SG 11202008513WA SG 11202008513W A SG11202008513W A SG 11202008513WA SG 11202008513W A SG11202008513W A SG 11202008513WA
- Authority
- SG
- Singapore
- Prior art keywords
- erbb3 antibodies
- immunised
- immunised anti
- erbb3
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1804094.9A GB201804094D0 (en) | 2018-03-14 | 2018-03-14 | ERBB3 Binding agents |
PCT/EP2019/056506 WO2019175359A1 (en) | 2018-03-14 | 2019-03-14 | De-immunised anti-erbb3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008513WA true SG11202008513WA (en) | 2020-10-29 |
Family
ID=61972871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008513WA SG11202008513WA (en) | 2018-03-14 | 2019-03-14 | De-immunised anti-erbb3 antibodies |
Country Status (9)
Country | Link |
---|---|
US (2) | US10975165B2 (en) |
EP (1) | EP3765156A1 (en) |
JP (1) | JP2021515544A (en) |
CN (1) | CN111818972A (en) |
AU (1) | AU2019233694A1 (en) |
CA (1) | CA3092610A1 (en) |
GB (1) | GB201804094D0 (en) |
SG (1) | SG11202008513WA (en) |
WO (1) | WO2019175359A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023002901A (en) * | 2020-09-14 | 2023-06-01 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof. |
WO2022078490A1 (en) * | 2020-10-15 | 2022-04-21 | 上海翰森生物医药科技有限公司 | Anti-erbb3 antibody or antigen-binding fragment thereof, and medical use thereof |
WO2023198138A1 (en) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | Antibody or antigen-binding fragment thereof and medical use thereof |
WO2024088388A1 (en) * | 2022-10-28 | 2024-05-02 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012003809A2 (en) * | 2009-08-21 | 2019-09-24 | Merrimack Pharmaceuticals Inc | isolated monoclonal antibody or antigen binding portion thereof, composition and method for treating cancer in an individual. |
SG184452A1 (en) | 2010-04-09 | 2012-11-29 | Aveo Pharmaceuticals Inc | Anti-erbb3 antibodies |
JP5995851B2 (en) * | 2010-10-18 | 2016-09-21 | メディアファーマ エス. アール. エル.Mediapharma S. R. L. | ErbB3 binding antibody |
KR101517320B1 (en) * | 2011-04-19 | 2015-05-28 | 메리맥 파마슈티컬즈, 인크. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
US9527913B2 (en) * | 2012-05-02 | 2016-12-27 | Symphogen A/S | Humanized pan-HER antibody compositions |
WO2014159915A1 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Her3 specific monoclonal antibodies for diagnostic and therapeutic use |
US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
-
2018
- 2018-03-14 GB GBGB1804094.9A patent/GB201804094D0/en not_active Ceased
-
2019
- 2019-03-14 CA CA3092610A patent/CA3092610A1/en active Pending
- 2019-03-14 SG SG11202008513WA patent/SG11202008513WA/en unknown
- 2019-03-14 AU AU2019233694A patent/AU2019233694A1/en not_active Abandoned
- 2019-03-14 WO PCT/EP2019/056506 patent/WO2019175359A1/en unknown
- 2019-03-14 JP JP2020543213A patent/JP2021515544A/en active Pending
- 2019-03-14 CN CN201980017723.3A patent/CN111818972A/en active Pending
- 2019-03-14 EP EP19711578.5A patent/EP3765156A1/en not_active Withdrawn
-
2020
- 2020-07-10 US US16/925,570 patent/US10975165B2/en active Active
-
2021
- 2021-03-02 US US17/189,860 patent/US20210189003A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200339702A1 (en) | 2020-10-29 |
US20210189003A1 (en) | 2021-06-24 |
US10975165B2 (en) | 2021-04-13 |
CN111818972A (en) | 2020-10-23 |
JP2021515544A (en) | 2021-06-24 |
AU2019233694A1 (en) | 2020-10-22 |
CA3092610A1 (en) | 2019-09-19 |
GB201804094D0 (en) | 2018-04-25 |
EP3765156A1 (en) | 2021-01-20 |
WO2019175359A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280780A (en) | Anti-tigit antibodies | |
IL279321A (en) | Anti-sirpα antibody | |
SG11202106214YA (en) | Novel anti-ccr8 antibody | |
IL280013A (en) | Anti-il36r antibodies | |
IL279352A (en) | Il-11ra antibodies | |
IL278010A (en) | Galectin-10 antibodies | |
IL273393A (en) | Novel anti-cd3epsilon antibodies | |
IL289112A (en) | Anti-tigit antibodies | |
IL277030A (en) | Antibodies | |
IL291068A (en) | Anti-cd73 antibodies | |
GB202110263D0 (en) | Anti-btla antibodies | |
IL284584A (en) | Anti-tigit antibodies | |
ZA202101177B (en) | Anti-btla antibody | |
SG11202008513WA (en) | De-immunised anti-erbb3 antibodies | |
GB201811368D0 (en) | Antibody | |
IL281594A (en) | Anti-klrg1 antibodies | |
GB201817172D0 (en) | Antibody | |
GB201905150D0 (en) | Ant-ige antibodies | |
GB201806084D0 (en) | Antibodies | |
GB201917480D0 (en) | Antibodies | |
GB201900732D0 (en) | Antibodies | |
IL289160A (en) | Anti-angpt2 antibodies | |
GB2598698B (en) | Affinity-maturated anti-ASICIa antibodies | |
GB201819952D0 (en) | Antibodies | |
GB201817313D0 (en) | Antibodies |